NeoImmuneTech Announces that the FDA has Allowed the Center for Cancer Research, National Cancer Institute to Proceed with an Investigational New Drug Application to Initiate a Clinical Trial for Hyleukin-7™ with Vaccines in Elderly Cancer Survivors
ROCKVILLE, Md.–(BUSINESS WIRE)–NeoImmuneTech, Inc. (NIT), a T cell-focused immunotherapeutics company, today announced that the U.S. Food and Drug Administration (FDA)…